曾子晏博士，教授級高級工程師，博士生導師，主要研究方向為：細胞診療及細胞質量管理體系建立、藥物基因組學與個體化診療產品開發、微生態與腫瘤、慢病的關聯性研究、腫瘤多肽藥物研發，涉及腦白質疏鬆症(Leukoaraiosis)、腺癌(adenocarcinoma)、不孕症(A-/Oligo-zoospermia) 等多個領域，曾在國際學術期刊發表SCI/IEEE學術論文70餘篇，申報4項PCT專利，20餘項中國發明專利，並開發出超過六項生技市場產品，對生物醫藥技術的研發、轉化商品套用、市場與資本運作等方面均有豐富的實踐經驗。
基本介紹
- 中文名：曾子晏
- 國籍：中國
- 民族：漢
- 畢業院校：1996.07 至1999.07，美國，史丹福大學醫學院，生物化學，博士後、1995.07 至1996.06，美國，史丹福大學醫學院，結構生物及免疫學，博士後、1989.06 至1993.05，中國台灣，清華大學原子科學院，輻射生物，博士
- 外文名：Chi-Meng Tzeng
- 別名：曾驥孟
- 職稱：教授
人物經歷,研究方向,主要成就,社會任職,所獲榮譽,代表性論文,英文論文,中文論文,專利,
人物經歷
教育經歷：
1989.06-1993.05：台灣清華大學原子科學院，輻射生物博士；
1995.07-1996.06：美國史丹福大學醫學院，結構生物及免疫學博士後；
1996.07-1999.07：美國史丹福大學醫學院，生物化學博士後。
主持/參與項目
18. 2023.01至2023.05，間充質幹細胞 (WJ-MSC/AD-MSC) 與免疫細胞 (NK/CIK/DC/γδ-T/CAR-T)產品製備及質量控制標準體系可行性研究，廈門市科技局-一般科技項目，3502Z20224010
17. 2022.07至2024.06，傷口癒合類和抑制HPV病毒類製劑有效成分鑑定與產品開發，廈門市科技局，2022CXY0115
16. 2020.12至2021.12，新型冠狀病毒肺炎(NCP)的診療研究與臨床轉化，國家科技部高端外國專家引進項目
15. 2020.09至2025.08，間充質幹細胞治療銀屑病及銀屑病型關節炎的臨床研究，國家重點研發計畫項目
14. 2020.02至2021.02，新型冠狀病毒肺炎(NCP)的診療研究與臨床轉化，廈門大學新型冠狀病毒防治應急科研攻關項目
13. 2019.06至2021.12，免疫抑制腫瘤細胞糖基化細胞庫的建立和細胞質量檢測中心管理控制體系的建立，廈門市科技計畫項目
12. 2018.01至2021.12，Gab2促進髓源性抑制細胞（MDSCs）功能介導肝癌發展的機制探究，國家自然科學基金
11. 2017.09至2020.09，IL-2激活NK細胞殺傷腫瘤的分子機制，XDHT2017359A
10. 2016.04至2018.04，非梗阻性無精症患者易感基因ZCCHC13甲基化位點篩查及其致病機理研究，福建省自然科學基金
9. 2014.01至2016.12，胃高分化與低分化腺癌分化差異的P53，PTEN等關鍵基因分子機理探索研究，國家自然科學基金
8. 2013.01至2014.12，深度測序技術篩選中國人華法林劑量相關基因，國家自然科學基金
7. 2012.06至2014.07，甲狀腺癌早期診斷檢測產品的研製，廈門市科技局“2012國家對台科技合作與交流基地項目”
6. 2012.03至2015.02，中國人群腦白質疏鬆症高風險基因多態性的研究及其分子診斷試劑的研發，福建省科技廳重點項目
5. 2012.01至2014.12，新型白血病分子診斷平台的建立，福建省科技廳自然科學基金計畫資助項目
4. 2011.10至2013.09，白血病快速篩查分子診斷平台建設及閩南地區白血病流行病學研究，廈門科技計畫項目
3. 2011.05至2013.05，精油的分子毒理研究及其安全性與功效評估體系建設，XDHT2011154A
2. 2011.07至2012.07，PD致病基因的預測研究，XDH2011309A
1. 2011.08至2014.07，華夏白血病和乳腺癌分子生物庫的建立，XDH2011367A
研究方向
細胞診療及細胞質量管理體系建立、藥物基因組學與個體化診療產品開發、微生態與腫瘤、慢病的關聯性研究、腫瘤多肽藥物研發，涉及腦白質疏鬆症(Leukoaraiosis)、腺癌(adenocarcinoma)、不孕症(A-/Oligo-zoospermia) 等多個領域
主要成就
曾在國際學術期刊發表SCI/IEEE學術論文70餘篇，申報4項PCT專利，20餘項中國發明專利，並開發出超過六項生技市場產品，對生物醫藥技術的研發、轉化商品套用、市場與資本運作等方面均有豐富的實踐經驗。於廈大任職期間承擔國家自然科學基金兩項，省市級科技項目四項。引領的藥學院轉化醫學平台期間合作建立了標準化的生物樣本資源庫並開展了多項基於高通量晶片技術（甲基化晶片、表達譜晶片、小RNA晶片等）的研究，先後與福建腫瘤醫院，廈門中山醫院，廈門第一醫院合作，並聯合台北病理中心，台大醫學院基因蛋白組中心，篩選出甲狀腺癌、乳腺癌、胃癌、癲 癇、腦白質疏鬆症、少精無精等多種疾病中的關鍵基因和潛在靶向治療生物標誌物進行基礎研究。且與佰香匯生技，艾德生醫藥、上海逍鵬、台灣芮寶生化、山東鉑 源等多家生物醫學產業公司合作，將科研成果轉化到市場中，將開發出相關檢測類試劑盒（EGFR, SMA, VitD3, PD等檢測試劑盒）及醫藥產品(Terpenoid vs Psoriasis牛皮鮮, Osteoporosis骨質疏鬆vs Protos and MSC間充質幹細胞vs wound healing傷口癒合)，充分實現了產學研相結合概念與產業化。
社會任職
廈門大學藥學院教授級高級工程師、博士生導師
Current Medicinal Chemistry 編審委員
Frontiers in Aging Neuroscience 特刊主編
所獲榮譽
廈門市引進高層次人才“雙百計畫”領軍型創業人才稱號
廈門大學2013優秀教師
霍英東基金評審專家
廈門市科技局評審專家
國家自然科學基金評審專家
國家火炬科技園招商與技術顧問
福建省及廈門市醫療器械體外診斷試劑專家
福建省特殊支持科技創新“雙百計畫”人才
廈門市”海納百川”特聘台灣專家人才
揚州市“綠揚金鳳計畫”創業領軍人才及江蘇省雙創人才一等獎
福建省引進台灣高層次人才“百人計畫
第四屆中國“網際網路+”大學生創新創業大賽優秀指導教師
福建省高層次人才現有人才B類
代表性論文
英文論文
77. Sun L, Zhang X, Wu S, Liu Y, Guerrero-Juarez CF, Liu W, Huang J, Yao Q, Yin M, Li J, Ramos R, Liao Y, Wu R, Xia T, Zhang X, Yang Y, Li F, Heng S, Zhang W, Yang M, Tzeng CM, Ji C, Plikus MV, Gallo RL, Zhang LJ. Dynamic interplay between IL-1 and WNT pathways in regulating dermal adipocyte lineage cells during skin development and wound regeneration. Cell Rep. 2023 Jun 16;42(6):112647. doi: 10.1016/j.celrep.2023.112647. Epub ahead of print. PMID: 37330908.
76. Zhang X, Retyunskiy V, Qiao S, Zhao Y, Tzeng CM. Alloferon-1 ameliorates acute inflammatory responses in λ-carrageenan-induced paw edema in mice. Sci Rep. 2022 Oct 6;12(1):16689. doi: 10.1038/s41598-022-20648-z. PMID: 36202869; PMCID: PMC9537184.
75. Zhao Y, Wang T, Chen Z, Ren H, Song P, Zhu Y, Liang S, Tzeng C. Development and Evaluation of a Thermosensitive In Situ Gel Formulation for Intravaginal Delivery of Lactobacillus gasseri. Pharmaceutics. 2022 Sep 13;14(9):1934. doi: 10.3390/pharmaceutics14091934. PMID: 36145685; PMCID: PMC9501376.
74. Chen Lin, Xuzhu Liu, Bingyi Zheng, RongqinKe, and Chi-Meng Tzeng, Liquid Biopsy, ctDNA Diagnosis through NGS, Life 2021,11(9), 890, MDPI. doi: 10.3390/life11090890.
73. Huang WQ, Lin Q,Chen S, Sun L, Chen Q, Yi K, Li Z, Ma Q, Tzeng CM. Correction for: Integratedanalysis of microRNA and mRNA expression profiling identifies BAIAP3 as a noveltarget of dysregulated hsa-miR-1972 in age-related white matter lesions. Aging(Albany NY). 2021 Jun 14;13(11):15688-15689. doi:10.18632/aging.203217. Epub2021 Jun 14. Erratum for: Aging (Albany NY).13:4674. PMID: 34127571; PMCID:PMC8221320.
72. Jianghong Cheng,Mingli Li , Chi-Meng Tzeng , Xingchun Gou and Shuai Chen, Suppression ofTumorigenicity 5 Ameliorates Tumor Characteristics of Invasive Breast CancerCells via ERK/JNK Pathway. Frontiers in Oncology, 28 July 2021,doi:10.3389/fonc.2021.621500.
71. ZhaoY, Lu C, Wang H, Lin Q, Cai L, Meng F, Tesfaye EB, Lai HC, Tzeng CM.Identification of hsa-miR-1275 as a Novel Biomarker Targeting for HumanEpilepsy of Unknown Etiology. Mol Ther Methods Clin Dev. 2020 Oct14;19:398-410.doi:10.1016/j.omtm.2020.10.005. PMID: 33251277; PMCID:PMC7677659.
70. LinTL, Lu CC, Lai WF, Wu TS, Lu JJ, Chen YM, Tzeng CM, Liu HT, Wei H, Lai HC. Roleof gut microbiota in identification of novel TCM-derived active metabolites.Protein Cell. 2021 May;12(5):394-410. doi:10.1007/s13238-020-00784-w. Epub 2020Sep 15. PMID: 32929698; PMCID: PMC8106560.
69. LinTL, Shu CC, Chen YM, Lu JJ, Wu TS, Lai WF, Tzeng CM, Lai HC, Lu CC. LikeCuresLike: Pharmacological Activity of Anti-Inflammatory Lipopolysaccharides FromGut Microbiome. Front Pharmacol. 2020 Apr 30;11:554. doi:10.3389/fphar.2020.00554.PMID: 32425790; PMCID: PMC7212368.
68. ZhaoY, Wang HL, Li TT, Yang F, Tzeng CM. Baicalin Ameliorates Dexamethasone-InducedOsteoporosis by Regulation of the RANK/RANKL/OPG Signaling Pathway. Drug DesDevel Ther. 2020 Jan 15;14:195-206. doi:10.2147/DDDT.S225516. PMID:32021104;PMCID: PMC6970258.
67. HuangWQ, Ye HM, Cai LL, Ma QL, Lu CX, Tong SJ, Tzeng CM, Lin Q. The Associations ofVariants With Leukoaraiosis in Chinese Population. Front Genet. 2019 Jul23;10:615. doi:10.3389/fgene.2019.00615. PMID: 31396257; PMCID: PMC6664056.
66. ZhuJ, Deng L, Chen B, Huang W, Lin X, Chen G, Tzeng CM, Ying M, Lu Z.Magnesium-dependent Phosphatase (MDP) 1 is a Potential Suppressor of GastricCancer. Curr Cancer Drug Targets. 2019;19(10):817-827.doi:10.2174/1568009619666190620112546. PMID: 31218958.
65. HuangJ, Alexey S, Li J, Jones T, Grande G, Douthit L, Xie J, Chen D, Wu X, MichaelM, Xiao C, Zhao J, Xie X, Xie J, Chen XL, Fu G, Alexander G, Tzeng CM.Correction: Unique CDR3 epitope targeting by CAR-T cells is a viable approachfor treating T-cell malignancies. Leukemia. 2019 Sep;33(9):2341.doi:10.1038/s41375-019-0484-y. Erratum for: Leukemia. 2019Sep;33(9):2315-2319.PMID: 31097784.
64. ZhaoY, Cai LL, Wang HL, Shi XJ, Ye HM, Song P, Huang BQ, Tzeng CM.1,25-Dihydroxyvitamin D3 affects gastric cancer progression by repressing BMP3promoter methylation. Onco Targets Ther. 2019 Mar 28;12:2343-2353.doi:10.2147/OTT.S195642. PMID: 30992671; PMCID: PMC6445188.
63. Huang WQ, Lin HN,Lin Q, Tzeng CM. Susceptibility Weighted Imaging (SWI) Recommended as a RegularMagnetic Resonance Diagnosis for Vascular Dementia to Identify IndependentIdiopathic Normal Pressure Hydrocephalus Before Ventriculo-Peritoneal (V-P)Shunt Treatment: A Case Study. Front Neurol. 2019 Mar 29;10:262.doi:10.3389/fneur.2019.00262. PMID: 30984097; PMCID: PMC6449466.
62. HuangJ, Alexey S, Li J, Jones T, Grande G, Douthit L, Xie J, Chen D, Wu X,Michael M,Xiao C, Zhao J, Xie X, Xie J, Chen XL, Fu G, Alexander G, Tzeng CM. Unique CDR3epitope targeting by CAR-T cells is a viable approach for treating T-cellmalignancies. Leukemia. 2019 Sep;33(9):2315-2319.doi:10.1038/s41375-019-0455-3. Epub 2019 Apr 8. Erratum in: Leukemia. 2019 May16; PMID: 30962578.
61. ChenS, Wang H, Li Z, You J, Wu QW, Zhao C, Tzeng CM, Zhang ZM. Interaction of WBP2with ERα increases doxorubicin resistance of breast cancer cells by modulatingMDR1 transcription. Br J Cancer. 2018 May 1;119(2):182-192.doi:10.1038/s41416-018-0119-5. PMID: 29937544; PMCID: PMC6048156.
60. HuangWQ, Yi KH, Li Z, Wang H, Li ML, Cai LL, Lin HN, Lin Q, Tzeng CM. DNAMethylation Profiling Reveals the Change of Inflammation-Associated ZC3H12D inLeukoaraiosis. Front Aging Neurosci. 2018 May 23;10:143.doi:10.3389/fnagi.2018.00143. PMID: 29875652; PMCID: PMC5974056.
59. LiZ, Chen S, Yang Y, Zhuang X, Tzeng CM. Novel biomarker ZCCHC13 revealed byintegrating DNA methylation and mRNA expression data in non-obstructiveazoospermia. Cell Death Discov. 2018 Feb 26;4:36.doi:10.1038/s41420-018-0033-x. PMID: 29531833; PMCID: PMC5841273.
58. ChenS, Zhang Y, Wang H, Zeng YY, Li Z, Li ML, Li FF, You J, Zhang ZM, Tzeng CM. WWdomain-binding protein 2 acts as an oncogene by modulating the activity of theglycolytic enzyme ENO1 in glioma. Cell Death Dis. 2018 Mar 1;9(3):347.doi:10.1038/s41419-018-0376-5. PMID: 29497031; PMCID: PMC5832848.
57. LiZ, Tzeng CM. Integrated Analysis of miRNA and mRNA Expression Profiles toIdentify miRNA Targets. Methods Mol Biol. 2018;1720:141-148.doi:10.1007/978-1-4939-7540-2_10. PMID: 29236256.
56. CaiLL, Huang WQ, Su ZY, Ye HM, Wang LS, Wu Y, Zhang ZY, Zhang W, Tzeng CM.Identification of two novel genes SLC15A2 and SLCO1B3 associated withmaintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017Dec 12;7(1):17379. doi:10.1038/s41598-017-17731-1. PMID: 29234073;PMCID:PMC5727167.
55. LinQ, Huang WQ, Ma QL, Lu CX, Tong SJ, Ye JH, Lin HN, Gu L, Yi KH, Cai LL, TzengCM. Incidence and risk factors of leukoaraiosis from 4683 hospitalizedpatients: A cross-sectional study. Medicine (Baltimore). 2017 Sep;96(39):e7682.doi:10.1097/MD.0000000000007682. PMID: 28953609; PMCID: PMC5626252.
54. ChenS, Wang H, Huang YF, Li ML, Cheng JH, Hu P, Lu CH, Zhang Y, Liu N, Tzeng CM,Zhang ZM. WW domain-binding protein 2: an adaptor protein closely linked to thedevelopment of breast cancer. Mol Cancer. 2017 Jul 19;16(1):128.doi:10.1186/s12943-017-0693-9. PMID: 28724435; PMCID: PMC5518133.
53. Kang C, Xia L, Chen Y, Zhang T, Wang Y, ZhouB, You M, Yuan Q, Tzeng CM, An Z, Luo W, Xia N. A novel therapeutic anti-HBVantibody with increased binding to human FcRn improves in vivo PK in mice andmonkeys. Protein Cell. 2018 Jan;9(1):130-134. doi:10.1007/s13238-017-0438-y.PMID: 28677103; PMCID:PMC5777975.
52. Li Z, Zhuang X, Zeng J, Tzeng CM. IntegratedAnalysis of DNA Methylation and mRNA Expression Profiles to Identify Key Genesin Severe Oligozoospermia. Front Physiol. 2017 May 12;8:261.doi:10.3389/fphys.2017.00261. PMID: 28553232; PMCID: PMC5427114.
51. Huang WQ, Lu CX, Zhang Y, Yi KH, Cai LL, LiML, Wang H, Lin Q, Tzeng CM. A Novel CCM2 Gene Mutation Associated withFamilial Cerebral Cavernous Malformation. Front Aging Neurosci. 2016 Sep21;8:220. doi:10.3389/fnagi.2016.00220. PMID: 27708576; PMCID: PMC5030299.
50. Cai LL, Liu GY, Tzeng CM. Genome-wide DNAmethylation profiling and its involved molecular pathways from one individualwith thyroid malignant/benign tumor and hyperplasia: A case report. Medicine(Baltimore). 2016 Aug;95(35):e4695. doi:10.1097/MD.0000000000004695. PMID:27583899; PMCID:PMC5008583.
49. Huang WQ, Ye HM, Li FF, Yi KH, Zhang Y, CaiLL, Lin HN, Lin Q, Tzeng CM. Analysis of genetic polymorphisms associated withleukoaraiosis in the southern Chinese population: A case-control study.Medicine (Baltimore). 2016 Aug;95(35):e3857. doi:10.1097/MD.0000000000003857.PMID: 27583843; PMCID: PMC5008527.
48. Li Z, Zheng Z, Ruan J, Li Z, Zhuang X, TzengCM. Integrated analysis miRNA and mRNA profiling in patients with severeoligozoospermia reveals miR-34c-3p downregulates PLCXD3 expression. Oncotarget.2016 Aug 16;7(33):52781-52796. doi:10.18632/oncotarget.10947. PMID: 27486773;PMCID: PMC5288148.
47. Li Z, Zheng Z, Ruan J, Li Z, Tzeng CM. ChronicInflammation Links Cancer and Parkinson's Disease. Front Aging Neurosci. 2016Jun 3;8:126. doi:10.3389/fnagi.2016.00126. PMID: 27375474; PMCID: PMC4891345.
46. Zhan L, Pan YZ, Chen L, Zhang H, Zhang H, SongJ, Tzeng CM, Sun CY. Prevalence of ABCB4 polymorphisms in gallstone disease inhan-Chinese population. Am J Transl Res. 2016 Feb 15;8(2):1218-27. PMID:27158408; PMCID: PMC4846965.
45. Hu P, Hsieh MH, Lei MJ, Cui B, Chiu SK, TzengCM. A Simple Algorithm for Population Classification. Sci Rep. 2016 Mar31;6:23491. doi: 10.1038/srep23491.PMID: 27030001; PMCID: PMC4814818.
44. Li Z, Lin H, Gu L, Gao J, Tzeng CM. HerbaCistanche (Rou Cong-Rong): One of the Best Pharmaceutical Gifts of TraditionalChinese Medicine. Front Pharmacol. 2016 Mar 1;7:41.doi:10.3389/fphar.2016.00041. PMID: 26973528; PMCID: PMC4771771.
43. Hu P, Han DX, Ruan RS, Zheng LM, Chou SH,Tzeng CM. Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790Mmutant NSCLC cell lines and xenografts. Oncotarget. 2016 Jun14;7(24):35741-35752. doi:10.18632/oncotarget.7140. PMID: 26848869; PMCID:PMC5094958.
42. Li Z, Zhong L, Gu L, Huang W, Shi X, Zhang X,An X, Lin Q, Tzeng CM. Association study of TREM2 polymorphism rs75932628 withleukoaraiosis or Parkinson's disease in the Han Chinese population. BMJ Open.2016 Jan 12;6(1):e009499. doi: 10.1136/bmjopen-2015-009499. PMID: 26758262;PMCID:PMC4716257.
41. Lin Q, Huang WQ, Tzeng CM. Corrigendum to:Genetic associations of leukoaraiosis indicate pathophysiological mechanisms inwhite matter lesions etiology. Rev Neurosci. 2015;26(5):607-8.doi:10.1515/revneuro-2015-0026. Erratum for: Rev Neurosci. 2015;26(3):343-58.PMID: 26267230.
40. Li Z, Lin Q, Huang W, Tzeng CM. Target genecapture sequencing in Chinese population of sporadic Parkinson disease.Medicine (Baltimore). 2015 May;94(20):e836. doi:10.1097/MD.0000000000000836.PMID: 25997059; PMCID:PMC4602860.
39. Lin Q, Huang WQ, Tzeng CM. Geneticassociations of leukoaraiosis indicate pathophysiological mechanisms in whitematter lesions etiology. Rev Neurosci. 2015;26(3):343-58.doi:10.1515/revneuro-2014-0082. Erratum in: Rev Neurosci. 2015;26(5):607-8.PMID: 25781674.
38. Zhuang X, Li Z, Lin H, Gu L, Lin Q, Lu Z,Tzeng CM. Integrated miRNA and mRNA expression profiling to identify mRNAtargets of dysregulated miRNAs in non-obstructive azoospermia. Sci Rep. 2015 Jan28;5:7922. doi:10.1038/srep07922. PMID: 25628250; PMCID: PMC4310093.
37. Sun C, Yan G, Li Z, Tzeng CM. A meta-analysisof the effect of preoperative biliary stenting on patients with obstructivejaundice. Medicine (Baltimore). 2014 Nov;93(26):e189. doi:10.1097/MD.0000000000000189.PMID: 25474436; PMCID: PMC4616392.
36. Cai LL, Ye HM, Zheng LM, Ruan RS, Tzeng CM.Circulating tumor cells (CTCs) as a liquid biopsy material and drug target.Curr Drug Targets. 2014;15(10):965-72. PMID: 25182470.
35. Huang S, Shen H, Li Z, Chiu SK, Ruan R, XiaoL, Tzeng CM. Identification of Vβ7.1_H3F7 as a therapeutic gene encoding TCRspecific to hepatocellular carcinoma. Curr Gene Ther. 2014;14(5):389-99.doi:10.2174/1566523214666140825124733. PMID: 25174578.
34. Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, LuZX, Tzeng CM. Structure, function, and pathogenesis of SHP2 in developmentaldisorders and tumorigenesis. Curr Cancer Drug Targets. 2014;14(6):567-88.doi:10.2174/1568009614666140717105001. PMID: 25039348.
33. Lu CX, Qing Lin, Huang WQ, Tzeng CM. Newmutations and polymorphisms of the ATP7B gene in sporadic Wilson disease. Eur JMed Genet. 2014 Sep;57(9):498-502. doi:10.1016/j.ejmg.2014.04.016. Epub 2014May 28. PMID: 24878384.
32. Ye HM, Lu YZ, Liang XM, Lin YZ, Li Y, ZhangZY, Tzeng CM. Clinical significance of combined testing of YKL-40 with CEA inChinese colorectal cancer patients. Clin Lab. 2014;60(3):397-405.doi:10.7754/clin.lab.2013.121027. PMID: 24697115.
31. Li Z, Lin Q, Ma Q, Lu C, Tzeng CM. Geneticpredisposition to Parkinson's disease and cancer. Curr Cancer Drug Targets.2014;14(3):310-21. doi:10.2174/1568009614666140312145936. PMID: 24628274.
30. Wang YQ, Song JJ, Han X, Liu YY, Wang XH, LiZM, Tzeng CM. Effects of angiopoietin-1 on inflammatory injury in endothelialprogenitor cells and blood vessels. Curr Gene Ther. 2014;14(2):128-35.doi:10.2174/1566523214666140307111138. PMID: 24606182.
29. Cai LL, Ye HM, Lv XN, Wu YL, Zhang HJ, ZhengLM, Tzeng CM. 25-(OH)VitD3, as a risk indicator in diagnosis of adenocarcinoma.Curr Drug Targets. 2013 Oct;14(11):1367-76. doi:10.2174/13894501113149990204.PMID: 23962296.
28. Ma Q, An X, Li Z, Zhang H, Huang W, Cai L, HuP, Lin Q, Tzeng CM. P268S in NOD2 associates with susceptibility to Parkinson'sdisease in Chinese population. Behav Brain Funct. 2013 May 7;9:19.doi:10.1186/1744-9081-9-19. PMID: 23651603; PMCID: PMC3662627.
27. Lv XN, Liu ZJ, Zhang HJ, Tzeng CM.Aromatherapy and the central nerve system (CNS): therapeutic mechanism and itsassociated genes. Curr Drug Targets. 2013 Jul;14(8):872-9.doi:10.2174/1389450111314080007. PMID: 23531112.
26. Liu GY, Liu KH, Li Y, Pan C, Su JQ, Liao HF,Yv RX, Li ZH, Yuan L, Zhang HJ, Tzeng CM, Xiong B. Novel cancerization marker,TP53, and its role in distinguishing normal tissue adjacent to cancerous tissuefrom normal tissue adjacent to benign tissue. World J Surg Oncol. 2012 Nov 21;10:252.doi:10.1186/1477-7819-10-252. PMID: 23170979; PMCID: PMC3544683.
25. Zhang HL, Ruan L, Zheng LM, Whyte D, Tzeng CM,Zhou XW. Association between class III β-tubulin expression and response topaclitaxel/vinorebine-based chemotherapy for non-small cell lung cancer: ameta-analysis. Lung Cancer. 2012 Jul;77(1):9-15.doi:10.1016/j.lungcan.2012.01.005. Epub 2012 Feb 4. PMID:22306125.
24. Chiu SK, Hsieh MH, Tzeng CM. Unique markerfinder algorithm generates molecular diagnostic markers. Int J Bioinform ResAppl. 2011;7(1):24-42. doi:10.1504/IJBRA.2011.039168. PMID: 21441095.
23. Lin MF, Tzeng CM, Dyakov YA, Ni CK.Photostability of amino acids: internal conversion versus dissociation. J ChemPhys. 2007 Jun 28;126(24):241104. doi:10.1063/1.2751150. PMID: 17614530.
22. Lin E, Hwang Y, Tzeng CM. A case study of theutility of the HapMap database for pharmacogenomic haplotype analysis in theTaiwanese population. Mol Diagn Ther. 2006;10(6):367-70.doi:10.1007/BF03256213. PMID: 17154653.
21. Jiang B, Zhu ZZ, Liu F, Hou LF, Gu J, Chen E,Tzeng CM, Zhu G. Prevalence of mutation in the epidermal growth factor receptorgene in Chinese patients with non-small cell lung cancer. Clin Oncol (R CollRadiol). 2006 Oct;18(8):635. doi:10.1016/j.clon.2006.06.001. PMID: 17051955.
20. Tsai NP, Wu YC, Chen JW, Wu CF, Tzeng CM, SyuWJ. Multiple functions of l0036 in the regulation of the pathogenicity islandof enterohaemorrhagic Escherichia coli O157:H7. Biochem J. 2006 Jan 15;393(Pt2):591-9. doi:10.1042/BJ20051201. PMID: 16248852; PMCID: PMC1360710.
19. Shyur LF, Chen CH, Lo CP, Wang SY, Kang PL,Sun SJ, Chang CA, Tzeng CM, Yang NS. Induction of apoptosis in MCF-7 humanbreast cancer cells by phytochemicals from Anoectochilus formosanus. J BiomedSci. 2004 Nov-Dec;11(6):928-39. doi:10.1159/000081840. PMID: 15591790.
18. Yang NS, Shyur LF, Chen CH, Wang SY, Tzeng CM.Medicinal herb extract and a single-compound drug confer similar complexpharmacogenomic activities in mcf-7 cells. J Biomed Sci. 2004May-Jun;11(3):418-22. doi:10.1159/000077111. PMID:15067226.
17. Ku WC, Lau WK, Tseng YT, Tzeng CM, Chiu SK.Dextran sulfate provides a quantitative and quick microarray hybridizationreaction. Biochem Biophys Res Commun. 2004 Feb 27;315(1):30-7.doi:10.1016/j.bbrc.2004.01.013. PMID:15013421.
16. Chiu SK, Hsu M, Ku WC, Tu CY, Tseng YT, LauWK, Yan RY, Ma JT, Tzeng CM. Synergistic effects of epoxy- and amine-silanes onmicroarray DNA immobilization and hybridization. Biochem J. 2003 Sep 15;374(Pt3):625-32. doi:10.1042/BJ20030486. PMID: 12809552; PMCID: PMC1223638.
15. Hsieh MH, Hsu WC, Chiu SK, Tzeng CM. Anefficient algorithm for minimal primer set selection. Bioinformatics. 2003 Jan22;19(2):285-6. doi:10.1093/bioinformatics/19.2.285. PMID: 12538252.
14. Lau WK, Chiu SK, Ma JT, Tzeng CM. Linearamplification of catalyzed reporter deposition technology on nylon membranemicroarray. Biotechniques. 2002 Sep;33(3):564, 566-70. doi:10.2144/02333st07.PMID: 12238767.
13. Ogawa N, Tzeng CM, Fraley CD, Kornberg A.Inorganic polyphosphate in Vibrio cholerae: genetic, biochemical, andphysiologic features. J Bacteriol. 2000 Dec;182(23):6687-93.doi:10.1128/JB.182.23.6687-6693.2000. PMID: 11073913;PMCID: PMC111411.
12. Tzeng CM, Kornberg A. The multiple activitiesof polyphosphate kinase of Escherichia coli and their subunit structuredetermined by radiation target analysis. J Biol Chem. 2000 Feb11;275(6):3977-83. doi:10.1074/jbc.275.6.3977.PMID: 10660553.
11. Tzeng CM, Kornberg A. Polyphosphate kinase ishighly conserved in many bacterial pathogens. Mol Microbiol. 1998 Jul;29(1):381-2.doi:10.1046/j.1365-2958.1998.00887.x. PMID: 9701829.
10. Ault-Riché D, Fraley CD, Tzeng CM, Kornberg A.Novel assay reveals multiple pathways regulating stress-induced accumulationsof inorganic polyphosphate in Escherichia coli. J Bacteriol. 1998 Apr;180(7):1841-7.doi:10.1128/JB.180.7.1841-1847.1998. PMID: 9537383; PMCID: PMC107098.
9. Tzeng CM, Percival L, Barber LD, Cooper S,Adams EJ, Stewart D, Parham P. HLA class I genotyping by cDNA sequence of aVietnamese family expressing a weak B46 antigen. Tissue Antigens. 1997May;49(5):519-22. doi:10.1111/j.1399-0039.1997.tb02790.x. PMID: 9174148.
8. Tzeng CM, Adams EJ, Gumperz JE, Percival L,Wells RS, Parham P, Barber LD. Peptides bound endogenously by HLA-Cw*0304expressed in LCL 721.221 cells include a peptide derived from HLA-E. TissueAntigens. 1996 Oct;48(4 Pt1):325-8. doi: 10.1111/j.1399-0039.1996.tb02652.x.PMID: 8946687.
7. Tzeng CM, Yang CY, Yang SJ, Jiang SS, Kuo SY,Hung SH, Ma JT, Pan RL. Subunit structure of vacuolar proton-pyrophosphatase asdetermined by radiation inactivation. Biochem J. 1996 May 15;316 ( Pt 1)(Pt1):143-7. doi:10.1042/bj3160143. PMID: 8645197; PMCID: PMC1217314.
6. Yang SJ, Jiang SS, Tzeng CM, Kuo SY, Hung SH,Pan RL. Involvement of tyrosine residue in the inhibition of plant vacuolarH(+)-pyrophosphatase by tetranitromethane. Biochim Biophys Acta. 1996 May2;1294(1):89-97. doi:10.1016/0167-4838(96)00005-2. PMID: 8639720.
5. Chien LF, Wu JJ, Tzeng CM, Pan RL. ATPase ofRhodospirillum rubrum requires three functional copies of beta subunit asdetermined by radiation inactivation analysis. Biochem Mol Biol Int. 1993Sep;31(1):13-8. PMID: 8260936.
4. Ma JT, Wu JJ, Tzeng CM, Pan RL. Functionalsize analysis of F-ATPase from Escherichia coli by radiation inactivation. J BiolChem. 1993 May 25;268(15):10802-7. PMID: 7684367.
3. Hsu LH, Tzeng CM, Pan RL. Functional size ofthe thylakoid phosphatases determined by radiation inactivation. FEBS Lett.1993 Feb 22;318(1):1-3. doi:10.1016/0014-5793(93)81314-p. PMID: 8436218.
2. Tzeng CM, Hsu LH, Pan RL. Inhibition oftonoplast ATPase from etiolated mung bean seedlings by fluorescein5'-isothiocyanate. Biochem J. 1992 Aug 1;285 ( Pt3)(Pt 3):737-43.doi:10.1042/bj2850737. PMID: 1386733; PMCID: PMC1132857.
1. Chow WM, Tzeng CM, Chen CS, Kuo SY, Wang MY,Pan RL. Inhibition of tonoplast ATPase by 2',3'-dialdehyde derivative of ATP.Plant Physiol. 1992 Jan;98(1):44-52. doi:10.1104/pp.98.1.44. PMID: 16668647;PMCID: PMC1080148.
中文論文
呂曉楠、葉輝銘、顧龍、曾驥孟*.多重RT-PCR聯合毛細管電泳法檢測BCR-ABL融合基因.檢驗醫學2014,03(9),227-233.
顧龍、肖芸、呂曉楠、葉輝銘、劉祝君、曾驥孟*.廈門大學附屬中山醫院 2005～2012 年新發急性髓性白血病初步分析. 中華臨床醫師雜誌2013,7(24):11388-11391.
李志明、安興凱、林青、馬琪林、曾驥孟*. 帕金森病LRRK2基因單核苷酸rs34778348：G＞A多態性分析.廈大學報2013,52(6).
張換敬，李怡，劉國彥，曾驥孟*. 新型靶向治療HER2過表達乳腺癌. 廣東醫學. 2013.34(3):476-479.（影響因子:0.14）
李怡，張換敬, 呂曉楠, 劉國彥, 葉輝銘, 林青, 曾驥孟*. 生物樣本信息資源庫的國內外研究進展. 中國醫藥生物技術. 2012,7(5): 369-372.(影響因子:0.286).
曾驥孟.臨床病毒學. 北京.科學出版社，2012. (2 chapters)
李怡，劉國彥，張換敬，鄭立謀，曾驥孟*.新型環狀引物螢光定量PCR檢測乳腺癌組織HER2基因mRNA表達水平方法的建立. 中華檢驗醫學雜誌. 2012.35(11):1000-1005.（影響因子:0.916）
萬巍巍,張換敬,葉輝銘,萬麗琴,蔡良良,鄭立謀,曾驥孟*.25-羥基維生素D3完全抗原的合成與鑑定.細胞與分子免疫學雜誌. 2011,27(11): 1173-1179.
專利
曾子晏、王薛婷、曾曉玲、鄭炳義、楊長明、曾才英，一種Rett綜合徵早期輔助診斷試劑盒，廈門大學，PCT/CN2023/089710
曾子晏、鄭炳義、王薛婷、楊長明、曾曉玲、曾才英，一種臍帶間充質幹細胞功能亞群及其套用，廈門大學，PCT/CN2023/077553
曾子晏、王薛婷、張凌娟、許韌，一種間充質幹細胞亞群及其套用，廈門大學，2023101913942
曾子晏、曾曉玲、王薛婷，一種女性生殖道分泌物的自采裝置，廈門大學，2022222448655
曾子晏，一種婦科抗菌抗炎中藥複方組合物及其套用，廈門大學，CN202210071145.5
曾子晏，一種用於女性生殖道抑菌抗炎的中藥組合物及其套用，廈門大學，CN202210046346.X
曾子晏、楊長明、鄭炳義、王薛婷、曾曉玲、曾才英，廈門大學，一種體外誘導外周血單個核細胞擴增NK細胞的培養基組合，CN202111329534.5
曾子晏、楊長明、鄭炳義、王薛婷、曾曉玲、曾才英，一種增強人外周血單核細胞免疫殺傷能力的方法及其套用，CN202111469797.6
曾子晏、李浩、陸榮森、王薛婷、楊長明、張卿紅，中藥組合物及其套用，郎中堂藥業（廈門）有限公司，CN202110552366.X
曾子晏、李浩、陸榮森、王薛婷、楊長明、張卿紅，促進傷口癒合的組合物及其用途，郎中堂藥業（廈門）有限公司，CN202110553287.0
曾子晏、楊長明、鄭炳義，一種抗腫瘤活性多肽及其套用，庶安永康（廈門）健康產業有限公司，CN2021104975392
曾子晏、劉祝君，一種能緩解憂鬱症的天然植物萃取組合物及其製備方法，佰香匯生物科技（廈門）有限公司，CN202110279763.4
曾子晏、劉祝君，一種能舒緩焦慮症的天然植物萃取組合物及其製備方法，佰香匯生物科技（廈門）有限公司，CN202110279768.7
曾子晏、胡敏煌、王薛婷、鄭炳義、曾才英、曾曉玲，一種預防冠狀病毒的消毒劑組合物，廈門大學，CN202110039450.1
曾子晏、胡敏煌、王薛婷、鄭炳義、曾才英、曾曉玲，一種預防冠狀病毒的多肽消毒劑組合，廈門大學，CN202110034714.4
曾子晏、王薛婷，一種用於核酸擴增的預裝pcr反應試劑及其製備方法，廈門大學，CN202011500628X
曾驥孟、宋萍、趙燁、胡鵬、陳帥、黃寶琪，一種加氏乳桿菌及其在製備預防早產藥物中的套用，南京工業大學，CN201811292997.7
曾驥孟、許曉玲、龔劍、唐乃平、蒙明慧、聶禮綿，一種利用免疫磁珠負向吸附聯合流式細胞法檢測循環腫瘤細胞的試劑盒的檢測方法，江蘇醫諾萬細胞診療有限公司，CN201810168914.7
曾驥孟、唐乃平、龔劍、方月、許曉玲，一種用於檢測外周血EGFR基因T790M突變的特異性引物和探針及試劑盒，江蘇醫諾萬細胞診療有限公司，CN201810489633.1
李芳芳、曾驥孟、胡鵬，一種套用微流體晶片分離外泌體的方法，江蘇醫諾萬細胞診療有限公司，CN201710158638.1曾驥孟、胡鵬、李芳芳，一種套用於外泌體捕獲的微流體晶片及其製備方法，庶安永康（廈門）健康產業有限公司，CN201710158652.1
胡鵬、曾驥孟、莊莉莉，一種用於間充質幹細胞體外培養和擴增的無血清培養基，江蘇醫諾萬細胞診療有限公司，CN201611222344.2
曾驥孟、蒙明慧、許曉玲、唐振洲、胡鵬，一種microRNA組合作為腫瘤標誌物輔助診斷多種腫瘤的試劑盒及其檢測方法，江蘇醫諾萬細胞診療有限公司，CN201610517797.1
曾驥孟、胡鵬、唐振州、蒙明慧、陳彪，一種喹唑啉類化合物的合成方法，江蘇醫諾萬細胞診療有限公司，CN201610352749.1
曾驥孟李志明顧龍莊炫，一種血清miRNA生物標誌物的套用，廈門大學，CN201410819428.9
曾驥孟李志明顧龍莊炫，一種血清miRNA生物標誌物組合物與套用，廈門大學，CN201410819430.6
曾驥孟；蔡良良；劉國彥；葉輝銘；顧龍，人類甲狀腺癌組織基因特異位點甲基化水平檢測引物及其套用，廈門大學，CN201410135857.4
劉祝君；曾驥孟；劉節喜；林天送；謝加鳳，一種脫除柑橘屬精油中農藥殘留的方法，佰香匯生物科技（廈門）有限公司，CN201310226414.1
劉祝君；曾驥孟；張換敬；呂曉楠，一種去除精油中呋喃香豆素的方法，廈門大學/佰香匯生物科技（廈門）有限公司，CN201310058217.3
曾驥孟；鄭立謀；李怡；張換敬，檢測HER2基因表達水平的實時螢光定量PCR試劑盒，廈門大學，CN201210227940.5
劉祝君；曾驥孟；陳康；劉節喜；朱洪珍；鄭聲煊；謝加鳳；伍宏；李煌基，一種脫除柑橘屬植物精油中呋喃香豆素類成分的方法，佰香匯生物科技（廈門）有限公司，CN201210005247.3
王薊斌；張海龍；阮力；曾驥孟；鄭立謀，用於預測B肝病毒引起的肝癌的引物、探針及試劑盒，廈門艾德生物技術研究中心有限公司，CN201110146841.X
朱冠山；趙翊均；曾驥孟，非小細胞肺癌療效相關的egfr基因突變的快速檢測，庶安永康（廈門）生物科技有限公司，CN200610027918.0
Chi-meng Tzeng ,Xue-ting Wang.Prepakaged polymerase Chain Reaction(PCR) reagent for nucleic acid amplification and method thereof.18/337,091（US）
Chi-meng Tzeng ,Min-huang Hu.Xue-ting Wang.Bing-yi Zheng.Cai-ying Zeng.Xiao-ling Zeng.Peptide disinfectant for preventing coronaviruses.18/350,803(US)
Chi-chan Chen，Wei-chi Ku，Sung-kay Chiu，Chi-meng Tzeng*. Photovoltaic device to accelerate the interaction among biomolecules. U-Vision Biotech Co.,Ltd. WO2003035825.
Chi-meng Tzeng*, Kung-ming Hsu,Wei-chi Ku,Grace Lau, Jing-tyan Ma and Sung-kay Chiu. Combination of epoxy and amine silanes for immobilizing and hybridizing nucleic acid molecules on a solid support. U-Vision Biotech Co.,Ltd. US20030059819.
Shean-jen Chen,Feng-ming Hsiu,Chien-hung Tsai,Chia-yuan Tsou and Chi-meng Tzeng*. Surface plasmon resonance shifting interferometry imaging system for biomolecular interaction analysis. U-Vision Biotech Co.,Ltd. US20030219809.
Chi-chan Chen，Sung-kay Chiu,Chi-meng Tzeng and Wei-chi Ku. Photovoltaic device to accelerate the interaction among biomolecules. U-Vision Biotech Co.,Ltd..US20030077600.
